Steven Cohen Crinetics Pharmaceuticals, Inc. Transaction History
Point72 Asset Management, L.P.
- $36.6 Billion
- Q3 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 2,300,643 shares of CRNX stock, worth $123 Million. This represents 0.32% of its overall portfolio holdings.
Number of Shares
2,300,643
Previous 2,780,856
17.27%
Holding current value
$123 Million
Previous $125 Million
5.65%
% of portfolio
0.32%
Previous 0.35%
Shares
20 transactions
Others Institutions Holding CRNX
# of Institutions
241Shares Held
79.5MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$337 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$334 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$315 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$265 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$239 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.88B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...